SALT LAKE CITY, Jan. 31, 2019 /PRNewswire-PRWeb/ -- As part of AZOVA 360™ mobile ehealth platform, which grants patient access to receive clinical counseling and behavioral therapy from pharmacists and physicians anywhere and anytime, patients will now have easier access to request and purchase a PGx test directly from their smartphone, tablet or workstation. The partnership between OneOme and AZOVA will allow pharmacists to identify patients who may benefit most from the RightMed test, patients to request the test, and providers to order the test, all through AZOVA's single-source cloud-based solution. This healthcare e-commerce feature will also use AZOVA's seamless Secure Message Rx™ and secure TeleHealth video stream to enable pharmacists to provide successful and secure consults with physicians and patients to help interpret the RightMed test results.

"This is a breakthrough partnership that underscores AZOVA's critical role as a middleware in providing accurate and transparent digital healthcare solutions to patients, pharmacists and physicians," stated AZOVA's SVP of Enterprise Sales and Operations, Ashton Maaraba. "AZOVA integrates into pharmacists' workflows, making execution at the point of care seamless. In today's world, point of care is not just a behind-the-bench service anymore; it's digital and everywhere too."

Pharmacists' distinct education, skills, and expanding role in healthcare make them uniquely qualified to help patients and physicians utilize PGx testing. By introducing the RightMed test to patients and providers, assisting in the physician's ordering process, and providing interpretation consults for patients and providers, pharmacists are positioned to champion processes for PGx testing and interpretation of results – and with it, a new level of care.

"We are thrilled to drive access to our RightMed test through AZOVA's clinical platform," said OneOme CEO, Paul Owen. "This modernized digital healthcare platform revolutionizes the availability of the RightMed test and test result interpretation by directly connecting the patient, pharmacist, and provider through a single digital experience."

The RightMed test covers 27 genes and hundreds of medications across many medical conditions, including psychiatry, oncology, cardiology, pain, and more. The combination of AZOVA and OneOme positions healthcare providers to focus on providing top-notch patient care driven by data insights and unique medication profile assessments anytime, anywhere.

"When we looked at forming partnerships in this healthcare space, we evaluate what public health benefit a partnership like this would serve and how meaningful it would be. With OneOme, we have built an important bridge that did not previously exist for patients, pharmacists, and physicians who use AZOVA," adds Cheryl Lee Eberting, MD and company CEO.


AZOVA's ease of implementation takes minutes-to-hours to deploy and requires no software-development kits or expensive customization. AZOVA is a single-solution platform that saves pharmacy, medical clinics, hospitals, employer sites and pharma time and money and which allows healthcare providers to focus on providing top-notch patient care. Sign up for a demo today at or call 800.44MYAZOVA to learn more about how AZOVA can help grow your business and provide your patients with a healthcare experience that will keep your patients coming back to you on AZOVA's Collaborative Clinical Care Platform.

About OneOme

OneOme was co-founded with Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit

Editor's Note: Mayo Clinic has financial investment in the technology referenced in this news release. The revenue that Mayo Clinic will receive is used to support its not-for-profit mission in patient care, education and research.